• One Health
  • Pain Management
  • Oncology
  • Geriatric & Palliative Medicine
  • Ophthalmology
  • Anatomic Pathology
  • Poultry Medicine
  • Infectious Diseases
  • Dermatology
  • Theriogenology
  • Nutrition
  • Animal Welfare
  • Radiology
  • Internal Medicine
  • Small Ruminant
  • Cardiology
  • Dentistry
  • Feline Medicine
  • Soft Tissue Surgery
  • Urology/Nephrology
  • Avian & Exotic
  • Preventive Medicine
  • Anesthesiology & Pain Management
  • Integrative & Holistic Medicine
  • Food Animals
  • Behavior
  • Zoo Medicine
  • Toxicology
  • Orthopedics
  • Emergency & Critical Care
  • Equine Medicine
  • Pharmacology
  • Pediatrics
  • Respiratory Medicine
  • Shelter Medicine
  • Parasitology
  • Clinical Pathology
  • Virtual Care
  • Rehabilitation
  • Epidemiology
  • Fish Medicine
  • Diabetes
  • Livestock
  • Endocrinology

Newer antidotal therapies (Proceedings)

Article

Antidotes can be divided into three broad catagories: chemical antidotes, pharmacologic antidotes, and functional antidotes. Chemical antidotes act directly on the toxicant to make it less toxic and/or more readily excreted.

Antidotes can be divided into three broad catagories: chemical antidotes, pharmacologic antidotes, and functional antidotes. Chemical antidotes act directly on the toxicant to make it less toxic and/or more readily excreted. Pharmacologic antidotes antagonize toxic agents at their receptor sites or through other macromolecules. Functional antidotes are agents that act on the symptoms of poisoning. In many cases, these antidotes have no real effect on the toxicant itself, but they lessen the severity of the clinical picture of the intoxicated patient.

Chemical antidotes: chelators

Deferoxamine

Deferoxamine (Desferal®, Ciba) is a chelating agent approved for use in humans for the treatment of acute iron poisoning, chronic iron overload and treatment of chronic aluminum overload in patients on chronic dialysis. It has been used off label to treat iron toxicosis in animals. Deferoxamine forms a chelate complex with free iron, which is then excreted in the urine and bile. Deferoxamine is most effective within the first 24 hours, before the iron has been distributed to the tissues. The extrapolated animal dose for iron toxicosis is 40 mg/kg, IM, every 4-8 hours. The IM route is preferred, as too rapid IV administration can cause hypotension and pulmonary edema. The efficacy of deferoxamine can be increased by giving ascorbic acid after the gut has been cleared of iron. The deferoxamine-iron complex gives a salmon pink color to the urine ("vin rose"). Continue to chelate until urine clears or until serum iron levels return to normal.

DMSA (2,3-dimercaptosucinic acid, succimer)

Succimer (Chemet®, McNeil Consumer Products) is approved for the treatment of childhood lead poisoning. It has also been used to treat arsenic and mercury poisoning and does not bind iron, calcium or magnesium. Succimer is available as 100 milligram capsules. It is a structural analog to BAL (British Anti-Lewisite, dimercaprol) but has less potential to cause nephrotoxicity. Succimer is preferred over Ca-EDTA and penicillamine, as succimer can be given while lead is still in the GI tract (the other 2 increase lead absorption), it comes in an oral form, it has a lower incidence of causing GI upset and it is also less likely than the others to induce Zn deficiency. Succimer, however, is more expensive than the other options (capsules are approximately $4 apiece).

Although not approved for animal use, there are published doses for treating lead toxicosis. The dose for dogs and cats is 10 mg/kg PO TID for 10 days (administer on empty stomach; per rectum if animal is vomiting). Dosing for caged birds is 25-35 mg/kg PO BID 5 days a week for 3-5 weeks. Higher doses (80 mg/kg) have caused death in cockatiels. It is not uncommon for there to be a post-chelation rebound (or elevation) of blood lead levels. Most of the time, this is due to redistribution of the lead from bone and tissue stores in animals chronically exposed to lead. If lead levels are still increased and the animal is still symptomatic, a repeated round of therapy can be pursued. If the animal is asymptomatic, there is no need to retreat.

Chemical antidotes: immunotoxicotherapy

Crotalidae polyvalent immune FAB (Ovine)

Crotalidae polyvalent immune Fab (ovine) (CroFab®, Fougera) is approved for the management of patients with North American crotalid snake envenomation. The antivenin has been show to cross react with 10 North American crotalid species (see Table 1). In a recent study, CroFab® was given to 115 dogs presented to several veterinary emergency hospitals in the western US. The CroFab® gave "excellent results" although some dogs did require more than one vial (average dosing was 1.25 vials). This study also reported significantly less reactions to the CroFab® product compared to Ft. Dodge/Wyeth equine antibody antivenin (advantage of Fab over whole IgG).

Table 1. Cross reactivity of Crotalidae polyvalent immune FAB

Early use (within 6 hours of snakebite) is recommended to prevent clinical deterioration and the occurrence of systemic coagulation abnormalities. Crotalid Fab is diluted in 250 mL of saline and infused over 60 minutes, with monitoring for development of an allergic reaction during the first 10 minutes. Recurrence of local symptoms of crotalinae envenomation following CroFab® treatment has been reported in people, probably due to the short half-life of the antivenin. Cost is approximately $1400/2 vials.

Digoxin immune Fab

Digoxin immune Fab (Digibind®, Burroughs Wellcome) is produced from specific digoxin antibodies from sheep and will bind directly to digoxin or digitoxin and inactivate it.

Antidigitoxin Fab fragments have an affinity for digoxin that is much higher than the affinity of digoxin for its sodium-potassium ATPase target. Digibind® has sufficient cross reactivity and can also be effective against bufotoxins (Bufo toads) and plants containing cardiac glycosides (see Table 2).

Table 2. Cross-reactivity of antidigoxin FAB fragment with plant cardiac glycosides

Treatment with Fab fragments should be considered in those patients who fail to respond to conventional therapy. Signs of severe toxicity might include severe ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), progressive bradyarrhythmias (severe sinus bradycardia), or second or third degree heart block not responsive to atropine. The dosage varies based on the amount of digoxin to be neutralized. The best situation is to have a human hospital run digoxin levels and then dosing is based on those results. The dose of Digibind® is calculated: Digibind® dose (number vials) = [Serum Digoxin Concentration (ng/mL) x Patient's weight (kg)] / 100. The next best method is to estimate the body load of digoxin ingested (almost impossible with toads or plants). Body load is estimated as dose ingested x 0.8. The formula is then: Digibind® dose (number vials) = [Body load (mg) / 0.5 (mg/vial)]. If either of these methods are not feasible then it is suggested that 1-2 vials be administered and the effects observed. Each vial of Digibind® contains 38 mg which will bind approximately 0.6 mg of digoxin or digitoxin. Reconstitute each vial with 4 mL of sterile water or isotonic saline. Administer slow IV over 30 minutes, infused through a 0.22 micron filter (if possible). Digibind® can be a life saving treatment however, it is expensive ($2200/5 vials).

Chemical antidotes: enzyme inhibitors

Fomepizole (4-MP, 4-methylpyrazole)

Fomepizole (Antizol-Vet®) is a competitive inhibitor of alcohol dehydrogenase. It was approved for use in dogs to treat ethylene glycol (EG) toxicosis in 1997. Each vial contains 1.5 g of fomepizole and the reconstituted solution is 50 mg/ml. Shelf life is 72 hours once reconstituted. The advantages of fomepizole are that is does not induce hyperosmolality, CNS depression, and diuresis (vs. ethanol). Dogs may be treated as late as 8 hrs post ingestion and still have a favorable prognosis. Fomepizole may still be effective as late as 36 hrs post-ingestion of EG. The recommended dosing regimen for dogs is an initial IV injection of 20 mg/kg (give over 15-30 minutes), followed by 15 mg/kg slow IV at 12 hours and again at 24 hours. A last dose of 5 mg/kg IV is given at 36 hours after the first injection. Since fomepizole slows down the metabolization of EG, serum levels may still be detectable at 72 hours after ingestion. If the EG test is still positive after the last dose continue treatment at 5 mg/kg IV every 12 hours until test is negative.

Fomepizole is not labeled for cats but preliminary clinical trial results suggest that high doses of fomepizole in the cat (125mg/kg slow IV infusion loading, then 31.25 mg/kg at 12, 24, 36 hrs post EG ingestion) are safe and effective when therapy is initiated within 3 hours following EG ingestion. [Note: at 3 hrs post lethal dose EG administration, 100% recovery with fomepizole, 25% recovery with ethanol. At 4 hrs post EG, 100% mortality with fomepizole and ethanol was noted in these studies]. Other than calcium oxalate crystals in the urine, no biochemical evidence of renal impairment was noted out to 2 weeks post EG exposure and fomepizole.

Pharmacologic antidotes: receptor antagonists

Flumazenil

Flumazenil (Romazicon®, Roche) is an imidazobenzodiazepine derivative, which antagonizes the CNS actions of benzodiazepines. Flumazenil binds to and rapidly displaces benzodiazepines from the benzodiazepine receptor, thereby reversing their sedative and anxiolytic effects within 1-2 minutes. It is indicated in people for diagnosis of benzodiazepine overdose and reversal of benzodiazepine sedation and respiratory depression. Use in animals is usually limited to those at risk of respiratory depression. The dose is 0.01 mg/kg, IV, for both dogs and cats and can be repeated if severe depression returns. The half-life for flumazenil is about 1 hour, so repeated injections may be needed. Flumazenil may also be given intratracheally in an emergency situation. Flumazenil is contraindicated in patients suspected of tricyclic antidepressant overdoses as it can cause seizures.

Atipamezole

Atipamezole (Antisedan®, Pfizer) is an α2-adrenergic antagonist labeled for use as a reversal agent for medetomidine, but it can also be used to treat several toxicoses. Atipamezole can be used to reverse other α2-adrenergic agonists (amitraz, xylazine, bromonidine, clonidine and tizanidine). Atipamezole quickly reverses the hypotension and bradycardia seen in these toxicoses. After IM administration in the dog, peak plasma levels occur in about 10 minutes. Atipamezole has an average plasma elimination half life of about 2-3 hours (vs. yohimbine half life of 1.5-2 hr in dogs) and may need to be repeated.

Functional antidotes

Bisphosphonates

Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone. Pamidronate (Aredia®, Novartis) inhibits osteoclastic bone resorption and was developed to treat hypercalcemia of malignancy in people. Pamidronate can be used in dogs for treating hypercalcemia secondary to cholecalciferol toxicosis. The recommended dose of pamidronate for dogs is 1.3 - 2.0 mg/kg as a slow IV infusion in 0.9% sodium chloride over 2-4 hours. The advantage of pamidronate over salmon calcitonin is that it has long lasting effects (may need to repeat once in 5-7 days). Do not use in combination with calcitonin. The downside of pamidronate is that it is expensive ($275-400/vial), however, when compared to length of hospitalization and the labor involved in the repeated doses of calcitonin, the cost is comparable.

New antidotal uses for other drugs (teaching old dogs new tricks)

Intralipids

Intralipids are lipid emulsions. Lipid emulsions are commonly used as a fat component for parenteral nutrition. While more studies are needed, lipid therapy is very exciting new treatment for lipid soluble toxicoses. Lipid use is based on human research investigating bupivacaine overdoses. The possible mechanism for lipid rescue is that the lipids bind to the fat soluble toxin ("lipid sink") and bound toxin is inactive.

Liposyn, or any other 20% lipid solution, can be given through a peripheral catheter and is relatively inexpensive. A bolus of 1.5 ml/kg is given (over 1 minute if cardiac arrest, slower otherwise), followed by 0.25 ml/kg/min for 30-60 minutes. This is repeated in four hours if the serum is clear. Lipid therapy can hasten recovery time in some cases.

There are possible complications to lipid therapy: significant lipemia, pancreatitis, transiently increased liver enzymes, volume overload and lipids can also remove antidotes and other therapies.

Cyproheptadine

Cyproheptadine(Periactin®, Merck) is an antihistamine (H1 blocker) that also has serotonin antagonistic activity. Cyproheptadine has been used in veterinary medicine for its antihistaminic and appetite-stimulant effects (cats) and is now being used to help treat serotonin syndrome. Serotonin syndrome is a condition caused by serotonin excess within the CNS and is characterized in dogs by tremors, seizures, hyperthermia, ataxia, vomiting, diarrhea, abdominal pain, excitation or depression, and hyperesthesia. Serotonin syndrome has been associated with the use of drugs that increase brain serotonin levels (e.g. selective serotonin reuptake inhibitors, amphetamines) in humans and after accidental ingestion of 5-hydroxytryptophan (serotonin precursor) in dogs. The recommended dose for dogs is 1.1 mg/kg PO or per rectum every 1-4 hours until signs subside.

N-acetylcysteine

N-acetylcysteine (NAC, mucomyst) is the N-acetyl derivative of L-cysteine, a naturally occurring amino acid. Although originally used as a mucolytic agent in people, NAC has become an important part of managing acetaminophen overdoses in people and animals. Because of NAC's ability to minimize oxidative damage to the liver from acetaminophen, NAC had been investigated for its ability to prevent damage from other hepatotoxins. A recent study on Amanita phalloides (death cap mushroom) poisoned people showed that the use of a protocol similar to that used for acetaminophen toxicosis (high dose) was effective in preventing permanent hepatic injury in 10 of 11 people.

Dantrolene

Dantrolene (Dantrium®, Procter & Gamble Pharm.) has been mostly used in veterinary medicine for the prevention and treatment of malignant hyperthermia syndrome. Dantrolene may also be used to treat the malignant hyperthermia-like reaction seen in dogs after the ingestion of hops (Humulus lupulus). Hops are used in the brewing of beer. Recommended dose of dantrolene is 2-3 mg/kg, IV, or 3.5 mg/kg, PO, as soon as possible after ingestion.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.